Your browser doesn't support javascript.
loading
Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.
Matute-Blanch, Clara; Villar, Luisa M; Álvarez-Cermeño, José C; Rejdak, Konrad; Evdoshenko, Evgeniy; Makshakov, Gleb; Nazarov, Vladimir; Lapin, Sergey; Midaglia, Luciana; Vidal-Jordana, Angela; Drulovic, Jelena; García-Merino, Antonio; Sánchez-López, Antonio J; Havrdova, Eva; Saiz, Albert; Llufriu, Sara; Alvarez-Lafuente, Roberto; Schroeder, Ina; Zettl, Uwe K; Galimberti, Daniela; Ramió-Torrentà, Lluís; Robles, René; Quintana, Ester; Hegen, Harald; Deisenhammer, Florian; Río, Jordi; Tintoré, Mar; Sánchez, Alex; Montalban, Xavier; Comabella, Manuel.
Afiliación
  • Matute-Blanch C; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Villar LM; Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain.
  • Álvarez-Cermeño JC; Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain.
  • Rejdak K; Department of Neurology, Medical University of Lublin, Lublin, Poland.
  • Evdoshenko E; MS Center (City Clinical Hospital 31), Saint Petersburg, Russia.
  • Makshakov G; First Pavlov Saint-Petersburg State Medical University, Saint-Petersburg, Russia.
  • Nazarov V; MS Center (City Clinical Hospital 31), Saint Petersburg, Russia.
  • Lapin S; First Pavlov Saint-Petersburg State Medical University, Saint-Petersburg, Russia.
  • Midaglia L; First Pavlov Saint-Petersburg State Medical University, Saint-Petersburg, Russia.
  • Vidal-Jordana A; First Pavlov Saint-Petersburg State Medical University, Saint-Petersburg, Russia.
  • Drulovic J; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • García-Merino A; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Sánchez-López AJ; Neurology Clinic, Clinical Centre of Serbia, Belgrade, Serbia.
  • Havrdova E; Neuroimmunology Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Saiz A; Neuroimmunology Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Llufriu S; Department of Neurology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic.
  • Alvarez-Lafuente R; Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
  • Schroeder I; Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
  • Zettl UK; Hospital Clínico San Carlos, Servicio de Neurología, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • Galimberti D; Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.
  • Ramió-Torrentà L; Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.
  • Robles R; University of Milan, Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.
  • Quintana E; Unitat de Neuroimmunologia i Esclerosi Múltiple, Servei de Neurologia, Hospital Universitari Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
  • Hegen H; Unitat de Neuroimmunologia i Esclerosi Múltiple, Servei de Neurologia, Hospital Universitari Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
  • Deisenhammer F; Unitat de Neuroimmunologia i Esclerosi Múltiple, Servei de Neurologia, Hospital Universitari Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
  • Río J; Medical University of Innsbruck, Department of Neurology, Innsbruck, Austria.
  • Tintoré M; Medical University of Innsbruck, Department of Neurology, Innsbruck, Austria.
  • Sánchez A; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Montalban X; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Comabella M; Unitat d'Estadística i Bioinformàtica, VHIR, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Brain ; 141(4): 1085-1093, 2018 04 01.
Article en En | MEDLINE | ID: mdl-29452342
The prognostic role of cerebrospinal fluid molecular biomarkers determined in early pathogenic stages of multiple sclerosis has yet to be defined. In the present study, we aimed to investigate the prognostic value of chitinase 3 like 1 (CHI3L1), neurofilament light chain, and oligoclonal bands for conversion to clinically isolated syndrome and to multiple sclerosis in 75 patients with radiologically isolated syndrome. Cerebrospinal fluid levels of CHI3L1 and neurofilament light chain were measured by enzyme-linked immunosorbent assay. Uni- and multivariable Cox regression models including as covariates age at diagnosis of radiologically isolated syndrome, number of brain lesions, sex and treatment were used to investigate associations between cerebrospinal fluid CHI3L1 and neurofilament light chain levels and time to conversion to clinically isolated syndrome and multiple sclerosis. Neurofilament light chain levels and oligoclonal bands were independent risk factors for the development of clinically isolated syndrome (hazard ratio = 1.02, P = 0.019, and hazard ratio = 14.7, P = 0.012, respectively) and multiple sclerosis (hazard ratio = 1.03, P = 0.003, and hazard ratio = 8.9, P = 0.046, respectively). The best cut-off to classify cerebrospinal fluid neurofilament light chain levels into high and low was 619 ng/l, and high neurofilament light chain levels were associated with a trend to shorter time to clinically isolated syndrome (P = 0.079) and significant shorter time to multiple sclerosis (P = 0.017). Similarly, patients with radiologically isolated syndrome presenting positive oligoclonal bands converted faster to clinically isolated syndrome and multiple sclerosis (P = 0.005 and P = 0.008, respectively). The effects of high neurofilament light chain levels shortening time to clinically isolated syndrome and multiple sclerosis were more pronounced in radiologically isolated syndrome patients with ≥37 years compared to younger patients. Cerebrospinal fluid CHI3L1 levels did not influence conversion to clinically isolated syndrome and multiple sclerosis in radiologically isolated syndrome patients. Overall, these findings suggest that cerebrospinal neurofilament light chain levels and oligoclonal bands are independent predictors of clinical conversion in patients with radiologically isolated syndrome. The association with a faster development of multiple sclerosis reinforces the importance of cerebrospinal fluid analysis in patients with radiologically isolated syndrome.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Enfermedades Desmielinizantes / Proteínas de Neurofilamentos / Bandas Oligoclonales / Proteína 1 Similar a Quitinasa-3 Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Brain Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Enfermedades Desmielinizantes / Proteínas de Neurofilamentos / Bandas Oligoclonales / Proteína 1 Similar a Quitinasa-3 Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Brain Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido